Globe News Wire
13 Jan 2026, 15:45 UTC · 35w ago
Verdict
Headline takes no side. We score BWXT +0.70 across five claims — strongly bullish.
+0.70strongly bullish
More positive than 81% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
The global radiopharmaceuticals market is projected to grow from $6.8 billion in 2024 to over $13.4 billion by 2033.
So whatStrong long-term growth forecasts and a 7.8% CAGR signal a bullish outlook for the sector's overall valuation.
More positive than 91% of claims this week
Major pharmaceutical companies are making multi-billion dollar acquisitions, including BMS's $4.1 billion purchase of RayzeBio and AstraZeneca's $2 billion acquisition of Fusion Pharmaceuticals.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 85% of claims this week
Industry leaders are investing in high-capacity infrastructure, such as NorthStar's new Wisconsin facility and ITM's tenfold production increase for Lutetium-177 in Germany.
More positive than 77% of claims this week
Approved radiopharmaceuticals are showing strong commercial performance, with Pluvicto earning $1.04 billion in the first nine months of 2024.
More positive than 77% of claims this week
Venture capital and strategic funding remain active, with ITM Radiopharma securing $205 million and AdvanCell raising $112 million.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 81% of ticker scores this week
BWXT Medical is pioneering a new FDA submission for a generator to ensure stable domestic supply of diagnostic procedures.
More positive than 76% of ticker scores this week
The company is growing its capabilities and pipeline through the acquisition of Fusion Pharmaceuticals.
More positive than 76% of ticker scores this week
The company is expanding its radiopharmaceuticals portfolio through a significant 4.1 billion dollar acquisition of RayzeBio.
More positive than 70% of ticker scores this week
The company is engaging in high-value collaborations and investments in oncology through a potential 1.1 billion dollar deal.
More positive than 66% of ticker scores this week
The company is advancing its pipeline with a pivotal Phase 3 trial for acute myeloid leukemia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
More positive than 95% of relationship scores this week
[a_to_b] Bristol-Myers Squibb purchased RayzeBio for US$ 4.1 billion.
More positive than 35% of relationship scores this week
[mutual] Eli Lilly entered a potential US$ 1.1 billion collaboration deal with Aktis Oncology.
−28.8%
Price is moving against the score
$147.19 vs $206.62 close before publication (Jan 12) · not market-adjusted
BWXT chart →
